Literature DB >> 25955388

MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma.

Hui Xu1, Yan-Wei Hu1, Jia-Yi Zhao1, Xiu-Mei Hu1, Shu-Fen Li1, Yan-Chao Wang1, Ji-Juan Gao1, Yan-Hua Sha1, Chun-Min Kang1, Li Lin1, Chuan Huang1, Jing-Jing Zhao1, Lei Zheng1, Qian Wang1.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. PHD finger protein 19 (PHF19) encodes a member of the polycomb group (PcG) of proteins that functions by maintaining the repressive transcriptional states of many developmental regulatory genes. In addition, it has been shown that miR-195 plays an important role in the molecular etiology of HCC; however, the effect and possible mechanism of PHF19 on HCC is unclear, and the association between PHF19 and miR-195 has seldom been addressed. In the present study, we investigated the carcinogenic activity and mechanism of PHF19 on HCC in vivo and in vitro. Our results showed that PHF19 is a potential target of hsa-miR-195-5p based on a bioinformatic analysis and results of a luciferase reporter assay. PHF19 was downregulated after transfection with hsa-miR-195-5p mimics. Moreover, we demonstrated that overexpression of PHF19 promoted hepatoma cell migration, invasion and proliferation in vitro. In contrast, overexpression of hsa-miR-195-5p in hepatoma cells reduced PHF19 expression, leading to suppression of hepatoma cell invasion, migration and proliferation in vitro. In addition, PHF19 markedly promoted the growth of xenograft tumors, while hsa-miR-195-5p markedly suppressed the growth of xenograft tumors in nude mice. These results provide evidence that PHF19 promotes HCC and is regulated by the tumor-suppressor, miR-195-5p.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25955388     DOI: 10.3892/or.2015.3957

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  23 in total

1.  Relationship between M6A methylation regulator and prognosis in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  Deliang Huang; Dejing Huang
Journal:  Heliyon       Date:  2022-10-07

2.  LncRNA DLX6-AS1 aggravates the development of ovarian cancer via modulating FHL2 by sponging miR-195-5p.

Authors:  Lijun Kong; Chengyan Zhang
Journal:  Cancer Cell Int       Date:  2020-08-05       Impact factor: 5.722

3.  Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.

Authors:  Yury O Nunez Lopez; Berta Victoria; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-20

4.  Differential expression of miR-195-5p in collapse of steroid-induced osteonecrosis of the femoral head.

Authors:  Pengfei Li; Pei Zhai; Zengjie Ye; Peng Deng; Yueguang Fan; Yirong Zeng; Zhihui Pang; Jianchun Zeng; Jie Li; Wenjun Feng
Journal:  Oncotarget       Date:  2017-06-27

5.  PHF19 promotes the proliferation, migration, and chemosensitivity of glioblastoma to doxorubicin through modulation of the SIAH1/β-catenin axis.

Authors:  Qing Deng; Jianbing Hou; Liying Feng; Ailing Lv; Xiaoxue Ke; Hanghua Liang; Feng Wang; Kui Zhang; Kuijun Chen; Hongjuan Cui
Journal:  Cell Death Dis       Date:  2018-10-15       Impact factor: 8.469

Review 6.  MicroRNA-195: a review of its role in cancers.

Authors:  Wanpeng Yu; Xiao Liang; Xiangdong Li; Yuan Zhang; Zhenqing Sun; Ying Liu; Jianxun Wang
Journal:  Onco Targets Ther       Date:  2018-10-17       Impact factor: 4.147

7.  Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.

Authors:  Jun Dai; Rujia Wei; Peihai Zhang; Beihua Kong
Journal:  J Transl Med       Date:  2019-06-06       Impact factor: 8.440

8.  MiR-497-5p, miR-195-5p and miR-455-3p function as tumor suppressors by targeting hTERT in melanoma A375 cells.

Authors:  Li Chai; Xiao-Jing Kang; Zhen-Zhu Sun; Ming-Feng Zeng; Shi-Rong Yu; Yuan Ding; Jun-Qin Liang; Ting-Ting Li; Juan Zhao
Journal:  Cancer Manag Res       Date:  2018-05-03       Impact factor: 3.989

9.  Clinical Value and Underlying Mechanisms of Upregulated LINC00485 in Hepatocellular Carcinoma.

Authors:  Xinyu Zhu; Yanlin Feng; Dingdong He; Zi Wang; Fangfang Huang; Jiancheng Tu
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

10.  Expression and Diagnostic Value of miR-497 and miR-1246 in Hepatocellular Carcinoma.

Authors:  Shuying Chen; Zile Fu; Shuzhan Wen; Xiaoyi Yang; Chengxuan Yu; Wenhan Zhou; Yong Lin; Yuan Lv
Journal:  Front Genet       Date:  2021-06-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.